Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Erythropoietic Protoporphyria
NCT01097044Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Apr 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started Apr 2010; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT01097044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097044.